How Vorapaxar Should be Integrated for ACS Patients in Practice - Ori Ben-Yehuda, MD

↳ This is a section part of Moment: CRT 2016 Coronary - Antiplatelet Controversies for ACS: How Will They Impact Our Practice?

Add this Moment to your Passport

Learn from this moment and keep it forever.
Add To Passport
$24.99
This moment is included in Simple Premium - Get started for free.
FREE with Simple Premium
Start your 30-day free trial
Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Preview

Summary

How Vorapaxar Should be Integrated for ACS Patients in Practice presented by Ori Ben-Yehuda, MD at CRT 2016

Add this Moment to your Passport

Learn from this moment and keep it forever.
Add To Passport
$24.99
This moment is included in Simple Premium - Get started for free.
FREE with Simple Premium
Start your 30-day free trial
Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Target Audience

  • Interventional Cardiologists
  • Interventional Fellows

Session Name: Antiplatelet Controversies for ACS: How Will They Impact Our Practice?

Track: Coronary

Learning Objectives

  • Update in advances in ACS & AMI Management

Other Components in this Moment

Overview
How Does One Implement a Protocol for Antiplatelet Therapy in ACS and During PCI? - Jeffrey Berger, MD, MS
Why I Prefer Ticagrelor - Dominick Angiolillo, MD, PhD, FSCAI
Why I Prefer Prasugrel - Paul Gurbel, MD, FSCAI
Why I Prefer Clopidogrel – Medical or Economic? - David Cox, MD, FSCAI
Will I Start Using Cangrelor? - Gary Schaer, MD, FSCAI
Transition Care PostPCI: Is it Safe to Switch Back to Clopidogrel? - Paul Gurbel, MD, FSCAI
Should Tirofiban Alter Our Approach? - Michael Lipinski, MD, PhD, FSCAI
How Does Atrial Fibrillation Change the Equation - WOEST Protocol? - C. Michael Gibson, MD
What is the Optimal Duration of DAPT after PCI? Insights from the DAPT Trial - David Cohen, MD, FSCAI
How Vorapaxar Should be Integrated for ACS Patients in Practice - Ori Ben-Yehuda, MD
Dare to Say No: Are We Using Too Many Drugs? Can We Drop Aspirin? - Roxana Mehran, MD, FACC, FSCAI
Loading Simple Education